IL-17A Blockade Treatment Success in Erythrodermic Pityriasis Rubra Pilaris

Background: Pityriasis rubra pilaris is an inflammatory skin disease with no known etiology or treatment algorithm. PRP patients have an increase in cytokines IL-17A, IL-17F, and IL-22. There are case reports and series that study treatment with agents that block these cytokines, but more research is needed. Our objective is to add to the literature on treatment of PRP with IL-17A blockers. Case: A 63-year-old man presented with erythrodermic pityriasis rubra pilaris that was diagnosed after biopsy and laboratory tests ruled out other conditions such as psoriasis and Sezary syndrome. He was successfully treated with IL-17 blockade. Conclusion: Our case demonstrates the successful use of IL-17A blockade for PRP, which suggests that it could be an effective future treatment.